Supplementary Figures 1-7 from Reduced NF1 Expression Confers Resistance to EGFR Inhibition in Lung Cancer
Year: 2023
Type: supplementary-materials
Abstract: PDF file 415K, Supplementary Figures 1-7. Figure S1, related to Figure 1. Genome-wide siRNA screen identifies determinants of resistance to erlotinib treatment. Figure S2, related to Figure 2. Reduced Nf1 expression in erlotinib-resistant EGFR-driven lung tumors. Figure S3, related to Figure 3. NF1 silencing confers resistance of lung adenocarcinoma cells to erlotinib. Figure S4, related to Figure 4. : NF1 downregulation activates MAPK pathway signaling. Figure S5, related to Figure 5. Low neurofibromin expressing cells respond to erlotinib when combined with MEK inhibition. Figure S6, related to Figure 6. Erlotinib-resistant murine EGFRL858R lung adenocarcinomas respond to combined EGFR and MEK inhibition. Figure S7, related to Figure 7. Reduced NF1 expression in erlotinib-resistant human NSCLC samples
Authors: Elza C. de Bruin, Catherine Cowell, Patricia H. Warne, Ming Jiang, Rebecca E. Saunders, Mary Ann Melnick, Scott Gettinger, Zenta Walther, Anna Wurtz, Guus J. Heynen, Daniëlle A.M. Heideman, Javier Gómez-Román, Almudena García-Castaño, Yixuan Gong, Marc Ladanyi, Harold Varmus, René Bernards, Egbert F. Smit, Katerina Politi, Julian Downward
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4362626532